The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents
Open accessAbstract
Some, but not all, antiresorptive agents have been shown to reduce the risk of nonvertebral fractures. Agents that significantly reduced nonvertebral fracture risk also appear to produce larger mean increases in bone mineral density (BMD) and reductions in biochemical markers (BCM) of bone turnover, compared with other agents. To examine the extent to which increases in BMD and reductions in BCM during antiresorptive therapy are associated with reductions in risk of nonvertebral fractures, we performed a meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis (i.e. prior vertebral fracture or low BMD) with available relevant data. A total of 18 such trials with usable data were identified, including a total of 2,415 women with incident nonvertebral fractures over 69,369 women-years of follow-up. Poisson regression was used to estimate the association between changes in BMD or BCM during the first year and overall reductions in risk of nonvertebral fractures (vs. the placebo group) across all trials. Larger increases in BMD and larger reductions in BCM were significantly associated with greater reductions in nonvertebral fracture risk. For example, each 1% increase in spine BMD at 1 yr was associated with an 8% reduction in nonvertebral fracture risk (P = 0.02). Mean BMD changes at the hip were smaller than at the spine, but the predicted net effect on fracture risk was the same; an agent that increases spine BMD by 6% at 1 yr reduces nonvertebral fracture risk by about 39%, and an agent that increases hip BMD by 3% at 1 yr reduces nonvertebral fracture risk by about 46%. The results also predict that a 70% reduction in resorption BCM would reduce risk by 40%, and a 50% reduction in formation BCM would reduce risk by 44%. It appears that either BMD or BCM changes are able to explain the effect of treatment, because a separate variable for treatment was not independently significant in any models. These data demonstrate that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures. Antiresorptive agents that do not produce large increases in BMD or large reductions in BCM do not appear to and would not be expected to decrease the risk of nonvertebral fractures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Self-citationFracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationStorm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Boivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00376-8 · Cited by 574
Overgaard, K., Hansen, M. A., Jensen, S. B., & Christiansen, C. (1992) · BMJ · doi:10.1136/bmj.305.6853.556 · Cited by 426
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Chesnut, C. H., McClung, M. R., Ensrud, K. E., Bell, N. H., Genant, H. K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. A., Delmas, P. D., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80134-x · Cited by 365
Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H. K., Wasnich, R. D., Ross, P., Miller, P. D., Licata, A. A., & Chesnut, C. H. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90350-x · Cited by 354
Schott, A. M., Cormier, C., Hans, D., Favier, F., Hausherr, E., Dargent-Molina, P., Delmas, P. D., Ribot, C., Sebert, J. L., Breart, G., et al. (1998) · Osteoporosis International · doi:10.1007/s001980050061 · Cited by 353
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6777 · Cited by 335
Meunier, P. J., & Boivin, G. (1997) · Bone · doi:10.1016/s8756-3282(97)00170-1 · Cited by 298
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
Self-citationPrevention of Nonvertebral Fractures by Alendronate: A Meta-analysis
Karpf, D. B. (1997) · JAMA · doi:10.1001/jama.1997.03540380073035 · Cited by 281
Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density
Bone, H. G. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.720 · Cited by 277
Cummings, S. R. (2000) · JAMA · doi:10.1001/jama.283.10.1318 · Cited by 249
Clinical Use of Biochemical Markers of Bone Remodeling: Current Status and Future Directions
Looker, A. C., Bauer, D. C., Chesnut III, C. H., Gundberg, C. M., Hochberg, M. C., Klee, G., Kleerekoper, M., Watts, N. B., & Bell, N. H. (2000) · Osteoporosis International · doi:10.1007/s001980070088 · Cited by 246
Self-citationTreatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial
Lufkin, E. G., Whitaker, M. D., Nickelsen, T., Argueta, R., Caplan, R. H., Knickerbocker, R. K., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1747 · Cited by 237
Rains, C., & Bryson, H. M. (1995) · Drugs & Aging · doi:10.2165/00002512-199507040-00007 · Cited by 224
Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study
Ross, P. D., Kress, B. C., Parson, R. E., Wasnich, R. D., Armour, K. A., & Mizrahi, I. A. (2000) · Osteoporosis International · doi:10.1007/s001980050009 · Cited by 207
Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk?
Faulkner, K. G. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.2.183 · Cited by 205
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women
Tonino, R. P. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3109 · Cited by 188
Adámi, S., Passeri, M., Ortolani, S., Broggini, M., Carratelli, L., Caruso, I., Gandolini, G., Gnessi, L., Laurenzi, M. W., Lombardi, A., et al. (1995) · Bone · doi:10.1016/s8756-3282(95)00262-6 · Cited by 142
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women
Bone, H. G. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.265 · Cited by 114
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Delmas, P. D. (2000) · Bone · doi:10.1016/s8756-3282(00)00301-x · Cited by 113
Clemmesen, B., Ravn, P., Zegels, B., Taquet, A. N., Christiansen, C., & Reginster, J.-Y. (1997) · Osteoporosis International · doi:10.1007/pl00004152 · Cited by 76
Preventing Fractures in Postmenopausal Women with Osteoporosis
Hochberg, M. C. (2000) · Drugs & Aging · doi:10.2165/00002512-200017040-00007 · Cited by 59
Self-citationMeunier, P. J. (1999) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1999.tb11682.x · Cited by 59
Power Law Models for the Mechanical Properties of Cancellous Bone
Currey, J. D. (1986) · Engineering in Medicine · doi:10.1243/emed_jour_1986_015_039_02 · Cited by 52
Sequential Parathyroid Hormone/Alendronate Therapy for Osteoporosis--Robbing Peter to Pay Paul?
Horwitz, M. J., Stewart, A. F., & Greenspan, S. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6658 · Cited by 47
Intermittent Cyclic Tiludronate in the Treatment of Osteoporosis
Reginster, J., Christiansen, C., Roux, C., Fechtenbaum, J., Rouillon, A., & Tou, K. (2001) · Osteoporosis International · doi:10.1007/s001980170126 · Cited by 41
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Metadata
- Authors
- Hochberg, M. C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-04-01
- Volume
- 87
- Issue
- 4
- Pages
- 1586-1592
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1987169166
- Cited by
- 480
- References
- 42
- FWCI
- 33.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.